Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 Beloud

@financialpost.com · 8 hours

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Biocytogen announced its partner IDEAYA Biosciences has dosed the first patient in a Phase 1 clinical trial for IDE034, a bispecific TOP1 ADC. This milestone triggers a $5 million payment to...

Read more Financialpost.com

1 Likes

1 Shares

1 Comments